IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
IGC Pharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
IGC Pharma's enterprise value was $20.17M on Nov 11, 2026, against $28.35M a year earlier. Over the last 5 years it ranged from $10.21M to $42.32M, with a median of $24.26M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $20.17M | -19.0% |
| 2025 | Dec 31, 2025 | $24.88M | +2.2% |
| 2024 | Dec 31, 2024 | $24.34M | +63.8% |
| 2023 | Dec 29, 2023 | $14.86M | +45.6% |
| 2022 | Dec 30, 2022 | $10.21M | -71.3% |
| 2021 | Dec 31, 2021 | $35.59M | -40.7% |
| 2020 | Dec 31, 2020 | $60.01M | +921.0% |
| 2019 | Dec 31, 2019 | $5.88M | +93.8% |
| 2018 | Dec 31, 2018 | $3.03M | – |
| 2017 | Dec 29, 2017 | -$228.69K | -261.7% |
| 2016 | Dec 30, 2016 | $141.42K | -79.8% |
| 2015 | Dec 31, 2015 | $699.26K | -49.2% |
| 2014 | Dec 31, 2014 | $1.38M | – |
| 2013 | Dec 31, 2013 | -$180.35K | -135.6% |
| 2012 | Dec 31, 2012 | $506.34K | – |
See a number that looks wrong?